Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed
on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal …

Diabetes Mellitus (DM) is a metabolic disorder that is spreading alarmingly around the
globe. Type-2 DM (T2DM) is characterized by low-grade inflammation and insulin resistance …

Highlights•Discovery of new drugs against cancer is of utmost importance.•Drug repurposing
is an alternative approach to traditional drug discovery.•It significantly reduces the R&D …

Meat proteins and associated by-products can be used as a source of bioactive hydrolysates
and peptides with potential for use as functional food ingredients. Functional foods are foods …

This article sheds light on the various scaffolds that can be used in the designing and
development of novel synthetic compounds to create DPP-4 inhibitors for the treatment of …

The use of anti-diabetic drugs has been increasing worldwide and the evolution of
therapeutics has been enormous. Still, the currently available anti-diabetic drugs do not …

Insulin resistance leads to impaired glucose metabolism by disrupting both insulin secretion
and sensitivity. Insulin resistance plays a key role in the pathophysiology of type 2 diabetes …

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising
therapeutic agents with potent anti-inflammatory properties and diverse clinical implications …

Diabetes Mellitus (DM) is amongst the most notable causes of years of life lost worldwide
and its prevalence increases perpetually. The disease is characterized as multisystemic …

Summary Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are a class of oral antidiabetic drugs
that improve glycaemic control without causing weight gain or increasing hypoglycaemic risk …